Healthcare Sector Analysis

223 tickers in Healthcare
Sorts the reports on this page by score, highest first.
Enliven Therapeutics, Inc.
ELVN·Healthcare
D ★Strong Sell
Current$48.80
Nov 14, 2026

Enliven's promising relcobatinib program and substantial cash reserves support a potential CML breakthrough, but single-asset clinical dependence, significant dilution and a demanding valuation create substantial downside risk.

Score
47
Ascendis Pharma A/S
ASND·Healthcare
B ★★★Hold
Current$275.39
Target$291.92
Return+6.0%
Nov 14, 2026

Ascendis Pharma combines exceptional rare-disease drug commercialization with expanding profitability and multiple pipeline catalysts, but its premium valuation and heavy YORVIPATH dependence leave limited room for execution setbacks.

Score
74
Erasca, Inc.
ERAS·Healthcare
F Avoid
Current$15.66
Nov 14, 2026

Erasca's promising pan-RAS oncology pipeline and substantial cash reserves create significant clinical upside, but its unproven commercialization, elevated valuation, and shareholder dilution make the investment highly speculative.

Score
37
Legend Biotech Corporation
LEGN·Healthcare
B ★★★Hold
Current$18.54
Target$34.18
Return+84.4%
Nov 13, 2026

Legend Biotech combines a clinically differentiated, growing CAR-T franchise with improving profitability and attractive sales-based valuation, but slowing U.S. adoption, single-product dependence, and negative cash flow constrain conviction.

Score
70
Liquidia Corporation
LQDA·Healthcare
B ★★★Hold
Current$58.12
Target$57.86
Return-0.4%
Nov 13, 2026

Liquidia's rapid YUTREPIA commercialization and high-margin PAH franchise offer substantial earnings potential, but product concentration, litigation settlement costs, and growth normalization limit near-term upside.

Score
66
Alcon Inc.
ALC·Healthcare
A ★★★★Buy
Current$71.83
Target$82.74
Return+15.2%
Nov 13, 2026

Alcon offers durable global eye-care demand, improving cash generation and a discounted historical valuation, but U.S. implant competition and weak reported capital efficiency could limit earnings growth.

Score
81
Scholar Rock Holding Corporation
SRRK·Healthcare
D ★Strong Sell
Current$43.16
Nov 13, 2026

Scholar Rock's FDA-approved muscle-targeted SMA therapy creates a differentiated commercial growth opportunity, but high cash burn, substantial dilution, and demanding adoption expectations constrain its investment appeal.

Score
50
Ionis Pharmaceuticals, Inc.
IONS·Healthcare
C ★★Sell
Current$28.33
Nov 12, 2026

Ionis has a differentiated RNA therapeutics platform, expanding approved-drug portfolio and valuable pipeline, but weak TRYNGOLZA adoption, substantial cash burn and uncertain profitability undermine its near-term investment appeal.

Score
55
Trevi Therapeutics, Inc.
TRVI·Healthcare
D ★Strong Sell
Current$14.82
Nov 12, 2026

Trevi Therapeutics could build a valuable chronic-cough franchise through Haduvio's late-stage clinical programs, but unproven commercialization, widening losses, clinical binary risk, and substantial dilution weaken its current investment appeal.

Score
45
Structure Therapeutics Inc.
GPCR·Healthcare
D ★Strong Sell
Current$20.95
Nov 12, 2026

Structure Therapeutics could become a meaningful oral obesity-drug developer through aleniglipron and its amylin pipeline, but unproven commercialization, rising cash burn, and shareholder dilution create substantial investment risk.

Score
48
Oruka Therapeutics, Inc.
ORKA·Healthcare
F Avoid
Current$107.17
Nov 12, 2026

Oruka's long-acting immunology antibodies show promising clinical efficacy and durability with substantial funding, but a demanding precommercial valuation, major dilution, and unresolved Phase 3 risks weaken its investment appeal.

Score
42
Tango Therapeutics, Inc.
TNGX·Healthcare
F Avoid
Current$25.73
Nov 12, 2026

Tango Therapeutics has promising PRMT5-targeted oncology programs and substantial liquidity, but its valuation depends on unproven pivotal outcomes while persistent losses and significant shareholder dilution threaten per-share value.

Score
42